Injectable Cancer Treatment Launched

Hikma Pharmaceuticals USA has launched Adriamycin (DOXOrubicin HCl) for Injection, in USP 10mg and 50mg dosage strengths.

Adriamycin (DOXOrubicin HCl) is an injectable cancer treatment, not a preventive vaccination.

Adriamycin (DOXOrubicin HCl) is an anthracycline topoisomerase II inhibitor indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement, following resection of primary breast cancer.

Additionally, Doxorubicin is indicated for the treatment of certain other cancers, such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, and metastatic bronchogenic carcinoma.

According to the company, sales of doxorubicin HCl 10mg and 50mg currently comprise approximately 15 percent of the market.